BioSpace News Archive

ProKidney Corp. announced the appointment of Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization.

Ondine Biomedical was awarded the TAYYABA HASAN IMPACT AWARD at the 18th World Congress of International Photodynamic Association in Tampere, Finland for demonstrating exceptional perseverance and clinical acumen.

Clearside Biomedical, Inc. announced today that the enrollment and dosing of participants is underway in ODYSSEY, its randomized, Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD).

Tonix Pharmaceuticals Holding Corp. , today announced that the first participant has been enrolled in a Phase 2 investigator-initiated, proof-of-concept study of TNX-1900 (potentiated intranasal oxytocin) for enhancing social safety learning in social anxiety disorder (SAD).

EyePoint Pharmaceuticals, Inc. today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

Gritstone bio, Inc. today announced that the Compensation Committee of the company’s Board of Directors granted four employees nonqualified stock options to purchase an aggregate of 30,700 shares of its common stock with an exercise price of $2.02, which is equal to the closing price of Gritstone’s common stock on July 10, 2023.

Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, and the Ministry of Health representing the Government of the Republic of Botswana announced a pathogen monitoring program at key ports of entry to identify new and emerging variants of SARS-CoV-2.

AxoSim, Inc., a leader in the development and application of human biomimetic platforms for neurological diseases, and Vyant Bio, Inc. (OTC: VYNT) (Vyant Bio) today announced that they have entered into a definitive agreement under which AxoSim will acquire the microBrain™-associated assets of Vyant Bio’s StemoniX subsidiary.

Can-Fite’s novel approach for the treatment of advanced liver cancer will be presented at the American Society of Clinical Oncology (ASCO) Breakthrough Meeting in Japan on August 4th 2023.

LianBio announced data from the Phase 3 EXPLORER-CN trial of mavacamten in Chinese symptomatic obstructive hypertrophic cardiomyopathy patients were accepted for a late-breaking presentation at the European Society of Cardiology Congress 2023 taking place August 25-28, 2023 in Amsterdam, Netherlands.